Onsdag 30 Oktober | 09:26:32 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-02-21 - Bokslutskommuniké 2023
2023-11-13 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-04 - Kvartalsrapport 2023-Q2
2023-07-03 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-07-22 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 - Årsstämma
2022-04-27 - Kvartalsrapport 2022-Q1
2022-02-16 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-07-15 - Extra Bolagsstämma 2021
2021-05-04 - Kvartalsrapport 2021-Q1
2021-04-29 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 - Årsstämma
2021-02-16 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-14 - Kvartalsrapport 2020-Q1
2020-04-29 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 - Årsstämma
2020-03-02 - Extra Bolagsstämma 2020
2020-02-14 - Bokslutskommuniké 2019
2019-11-08 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-15 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 - Kvartalsrapport 2019-Q1
2019-05-14 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-27 - Kvartalsrapport 2018-Q2
2018-06-04 - X-dag ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 - Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2023-10-20 00:06:05

The shareholders of IRRAS AB (publ), org.nr 556872-7134 ("the Company"), are hereby invited to the extraordinary general meeting to be held on Monday 13 November 2023 at 16.00 CET at the premises of Setterwalls Advokatbyrå at Sturegatan 10 in Stockholm.

Notice of Attendance

A shareholder who which to participate in the general meeting shall:

i. be entered in the register of shareholders maintained by Euroclear Sweden AB by the record date Friday 3 November 2023; and
ii. notify the Company of their attendance no later than Tuesday 7 November 2023.

Notification of participation shall be sent by mail to IRRAS AB (publ), Attn: Tore Linghede, P.O Box 160, SE-101 23 Stockholm, Sweden or by e-mail to EGM@irras.com.The notification shall state name, personal registration number/company registration number, address and telephone number, number of shares held and proxies if applicable.

Nominee registered shares

Shareholders who have had their shares registered in the name of a nominee must temporarily register the shares in their own name so that the shareholder is entered in the share register as of Friday 3 November 2023. Such registration may be temporary (so-called voting rights registration) and shall be requested from the nominee in accordance with the nominee's procedures at such time in advance as the nominee may determine. Voting rights registrations made on or before Tuesday 7 November 2023 will be taken into account in the preparation of the share register.

Proxies

Shareholders represented by proxy shall issue a written and dated power of attorney. The power of attorney may not be older than one year unless indicated that it is valid for a longer period, not exceeding five years. If the proxy is issued by a legal person, a certified copy of the registration certificate or similar papers of authorisation are also required. Power of attorney, registration certificates and other authorisation documents must be available for the Meeting and, in order to facilitate entry to the Meeting, sent to the Company at the above address, no later than 7 November 2023. Proxy forms for shareholders who wish to participate in the Meeting by proxy will be made available on the Company's website www.irras.com.

Proposed agenda

1. Opening of the meeting and election of chairman of the meeting
2. Preparation and approval of the voting list
3. Election of one or two persons who shall approve the minutes of the meeting
4. Determination of whether the meeting has been duly convened
5. Approval of the agenda
6. Determination of the number of board members.
7. Election and removal of board members.
8. Determination of fees to the board members.
9. Resolution that the guidelines for remuneration to the senior executives shall no longer apply after the delisting of IRRAS' shares from Nasdaq Stockholm.
10. Resolution that the principles regarding the appointment of members of the nomination committee shall no longer apply after the delisting of IRRAS' shares from Nasdaq Stockholm.
11. Closing of meeting

Proposed resolutions

Proposals under items 6 - 8 will be communicated at the latest in connection with the general meeting.

Shareholders right to submit questions

The shareholders are reminded of their right, in accordance with Chapter 7, Section 32 of the Swedish Companies Act, to request information from the board of directors and the CEO.

Other

As of 23 October 2023, there are a total of 1,133,078,240 ordinary shares and votes in the Company. There are no class C shares issued. The Company does not hold any of its own shares. For information about how your personal data will be processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Meeting documents

Proxy forms and other documents required by the Companies Act will be available at the Company and will be sent free of charge to any shareholder who requests them and provides his/her postal address. The documents are also available on the Company's website www.irras.com.

_____

Stockholm, October 2023

Board of directors